Key Points
- Director Bruce Cozadd sold 6,000 shares on April 1 at an average price of $190.50 for about $1.143M, reducing his stake by 1.54% to 384,682 shares; the sale was executed under a pre-arranged Rule 10b5‑1 trading plan and disclosed to the SEC.
- Jazz reported quarterly EPS of $6.64 (vs. $6.49 est.) and revenue of $1.20 billion (vs. $1.17B est.), with revenue up 8.1% year-over-year despite a negative net margin of 8.35%.
- Analyst sentiment is broadly positive with an average rating of "Moderate Buy" and an average price target of $215.38, while several firms have recently raised targets (e.g., Wells Fargo to $250, Morgan Stanley to $226).
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Get Free Report) Director Bruce Cozadd sold 6,000 shares of the company's stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $190.50, for a total value of $1,143,000.00. Following the transaction, the director directly owned 384,682 shares in the company, valued at $73,281,921. The trade was a 1.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Jazz Pharmaceuticals Stock Performance
NASDAQ JAZZ opened at $186.95 on Friday. The company has a market cap of $11.51 billion, a P/E ratio of -31.31, a PEG ratio of 0.33 and a beta of 0.23. The company has a fifty day simple moving average of $177.39 and a 200 day simple moving average of $161.91. The company has a current ratio of 1.86, a quick ratio of 1.67 and a debt-to-equity ratio of 1.00. Jazz Pharmaceuticals PLC has a 12-month low of $95.49 and a 12-month high of $198.00.
Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings data on Wednesday, February 25th. The specialty pharmaceutical company reported $6.64 earnings per share for the quarter, beating analysts' consensus estimates of $6.49 by $0.15. The firm had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.17 billion. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 6.87%. The business's quarterly revenue was up 8.1% compared to the same quarter last year. During the same period last year, the firm earned $6.51 earnings per share. Sell-side analysts predict that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of analysts have commented on JAZZ shares. Royal Bank Of Canada boosted their price objective on Jazz Pharmaceuticals from $191.00 to $195.00 and gave the stock an "outperform" rating in a report on Wednesday, February 25th. TD Cowen reaffirmed a "buy" rating on shares of Jazz Pharmaceuticals in a research report on Thursday, January 29th. Weiss Ratings restated a "sell (d+)" rating on shares of Jazz Pharmaceuticals in a research note on Friday, March 27th. Wells Fargo & Company lifted their price objective on shares of Jazz Pharmaceuticals from $235.00 to $250.00 and gave the stock an "overweight" rating in a report on Wednesday, February 25th. Finally, Morgan Stanley increased their target price on shares of Jazz Pharmaceuticals from $225.00 to $226.00 and gave the company an "overweight" rating in a report on Wednesday, February 25th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $215.38.
Check Out Our Latest Stock Report on Jazz Pharmaceuticals
Institutional Trading of Jazz Pharmaceuticals
A number of large investors have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP raised its stake in Jazz Pharmaceuticals by 11.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,836,652 shares of the specialty pharmaceutical company's stock valued at $373,855,000 after acquiring an additional 298,815 shares during the period. Essex Investment Management Co. LLC bought a new position in Jazz Pharmaceuticals during the third quarter worth about $2,697,000. Kennedy Capital Management LLC purchased a new position in shares of Jazz Pharmaceuticals in the second quarter worth about $1,100,000. Wedge Capital Management L L P NC bought a new stake in shares of Jazz Pharmaceuticals in the third quarter valued at approximately $27,834,000. Finally, Sequoia Financial Advisors LLC purchased a new stake in shares of Jazz Pharmaceuticals during the 3rd quarter valued at approximately $605,000. Hedge funds and other institutional investors own 89.14% of the company's stock.
About Jazz Pharmaceuticals
(
Get Free Report)
Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company's research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz's product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.
Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
